Selectivity and potency of the retroprogesterone dydrogesterone in vitro

other OA: closed public-domain-us
View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-13

Dydrogesterone and its metabolite 20α-dihydrodydrogesterone exhibit primarily progestogenic effects in vitro with less pronounced anti-androgenic potential compared to progesterone, and no clinically relevant androgenic, estrogenic, glucocorticoid, or mineralocorticoid activities.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Dydrogesterone is widely used for menstrual disorders, endometriosis, threatened and habitual abortion and postmenopausal hormone replacement therapy. Although progestins have a promiscuous nature, dydrogesterone does not have clinically relevant androgenic, estrogenic, glucocorticoid or mineralocorticoid activities. To date, systematic biochemical characterization of this progestin and its active main metabolite, 20α-dihydrodydrogesterone, has not been performed in comparison to progesterone. The objective of this study was to evaluate the selectivity and potential androgenic/antiandrogenic effects of dydrogesterone and its metabolite in comparison to progesterone and medroxyprogesterone acetate by analyzing their interference with AR signaling in vitro. We characterized dydrogesterone and its metabolite for their binding and transactivation of androgen and other steroid hormone receptors and for their potential inhibitory effects against androgen biosynthetic enzymes, 17β-hydroxysteroid dehydrogenase types 3 and 5 and 5α-reductase types 1 and 2. We found that dydrogesterone resembled progesterone mainly in its progestogenic effects and less in its androgenic, anti-androgenic, glucocorticoid and antiglucocorticoid effects; whereas, 20α-dihydrodydrogesterone showed reduced progestogenic potency with no androgenic, glucocorticoid and mineralocorticoid effects. Effects on the androgen and glucocorticoid receptor differed depending on the technology used to investigate transactivation. Progesterone, but not dydrogesterone and 20α-dihydrodydrogesterone, exerted anti-androgenic effects at the pre-receptor level by inhibiting 5α-reductase type 2. Dydrogesterone, 20α-dihydrodydrogesterone and progesterone inhibited the biosynthesis of testosterone catalyzed by 17β-hydroxysteroid dehydrogenase types 3 and 5; however, due to their micromolar K(i) values, these activities appeared to be not of relevance at therapeutic levels. Overall, our data show that the anti-androgenic potential of dydrogesterone and 20α-dihydrodydrogesterone is less pronounced compared to progesterone.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Androgen Receptor Antagonists Dydrogesterone Progestins 17-Hydroxysteroid Dehydrogenases 17-Hydroxysteroid Dehydrogenases 5-alpha Reductase Inhibitors 5-alpha Reductase Inhibitors Androgen Receptor Antagonists Binding, Competitive Binding Sites Cell Line Dydrogesterone Dydrogesterone Estrogen Receptor alpha Estrogen Receptor alpha Estrogen Receptor alpha Estrogen Receptor alpha Humans Progestins Receptors, Androgen

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-23T06:15:44.889181+00:00
pubmed
last seen: 2026-05-13T22:16:48.482574+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine